Clinical Trial

Systemic Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia

Study acronym: MDRBP-TCM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicenter prospective observational cohort study of hospitalized patients with multidrug-resistant bacterial pneumonia. The study will compare patients who receive systemic traditional Chinese medicine treatment during routine clinical care with those who do not receive systemic traditional Chinese medicine treatment. Systemic traditional Chinese medicine treatment may include Chinese herbal decoctions, oral Chinese patent medicines, or Chinese medicine injections. The primary objective is to evaluate whether systemic traditional Chinese medicine treatment is associated with a lower risk of lower respiratory tract infection events within 180 days after hospital discharge. Secondary outcomes include mortality, rehospitalization, bacterial clearance, clinical cure at hospital discharge, duration of antibacterial therapy, pneumonia-related clinician-reported and patient-reported outcome scores, health-related quality of life, inflammatory markers, imaging changes, safety outcomes, and direct medical costs.
Trial Details
NCT Number NCT07726095
Lead Sponsor Henan University of Traditional Chinese Medicine
Conditions Multi Drug Resistant Infections, Pneumnia
Enrollment 528 participants
Start Date 2026-08-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28